Effect of Dapagliflozin in The Prevention of Iodinated Contrast Media Induced Acute Kidney Injury

Effect of Dapagliflozin in The Prevention of Acute Kidney Injury Caused by Iodinated Contrast Media: A Randomized Placebo-Controlled Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170609034406N11

Enrollment

Registered

2024-01-25

Start date

2023-12-27

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury caused by iodinated contrast agents. Acute kidney failure

Interventions

Intervention 1: Intervention group (Dapagliflozin + standard care): 40 patients will be included in the study according to the inclusion and exclusion criteria, and will recieve 10 mg of Dapagliflozin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults aged 18 years or older Patients who are candidates for CT scan and receive Iodized Contrast Agents

Exclusion criteria

Exclusion criteria: Patients with underlying renal failure with GFR less than 30 Patients with liver failure (Child-Pugh stage B and C) Patients with heart failure Pregnant and lactating women The presence of chronic infection or autoimmune diseases History of taking Dapagliflozin Diabetic patients with Diabetic foot ulcers Patients are susceptible to ketoacidosis Alcoholic patients Patients with pancreatic failure History of allergy to Dapagliflozin Patients with osteoporosis Concomitant use of nephrotoxic drugs such as Calcineurin Inhibitors , Aminoglycosides, Vancomycin, Amphotericin B Participation in other clinical studuies

Design outcomes

Primary

Measure	Time frame
Urine KIM1 (Kidney Injury Molecule-1) level. Timepoint: At the beginning and end of the study. Method of measurement: ELISA Kit.;Serum BUN (Blood urea nitrogen) and Creatinine level. Timepoint: At the beginning and end of the study. Method of measurement: AutoAnalyzer.;Urine and Serum NGAL(Neutrophil Gelatinase Associated Lipocalin) level. Timepoint: At the beginning and end of the study. Method of measurement: ELISA Kit.	—

Measure

Time frame

Urine KIM1 (Kidney Injury Molecule-1) level. Timepoint: At the beginning and end of the study. Method of measurement: ELISA Kit.;Serum BUN (Blood urea nitrogen) and Creatinine level. Timepoint: At the beginning and end of the study. Method of measurement: AutoAnalyzer.;Urine and Serum NGAL(Neutrophil Gelatinase Associated Lipocalin) level. Timepoint: At the beginning and end of the study. Method of measurement: ELISA Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Gharekhani

Tabriz University of Medical Sciences

gharekhania@tbzmed.ac.ir0098413372250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026